File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong

TitleOutcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong
Authors
Issue Date2004
PublisherAmerican Medical Association. The Journal's web site is located at http://www.archoto.com
Citation
Archives Of Otolaryngology - Head And Neck Surgery, 2004, v. 130 n. 6, p. 770-772 How to Cite?
AbstractObjective: To evaluate the current clinical practice of follow-up and the outcomes of patients with raised Epstein-Barr virus (EBV) antibody levels but without pathological evidence of nasopharyngeal carcinoma (NPC) for a possible risk of developing NPC in the future. Design: Retrospective review of prospectively collected database. Setting: Tertiary referral otorhinolaryngology center. Patients: The study population comprised 66 patients (27 male and 39 female; median age, 43.5 [range, 9-78] years) who presented in 1997 with a positive EBV IgA viral capsid antigen titer but a negative nasopharyngeal biopsy result. Main Outcome Measures: The detection of NPC and EBV seroconversion rate. Results: Of the 66 patients studied, 14 had a positive family history of NPC. Fourteen patients (27%) were excluded because of loss of contact or refusal of follow-up. The median follow-up period of the remaining 52 patients was 54.5 months (range, 12-64 months). Of these 52 patients, 39 (75%) had initial nasendoscopic finding described as completely normal. During the follow-up period, NPC was diagnosed in 1 patient (2%) 18 months after first biopsy. The initial nasendoscopy and histological findings in this patient were normal despite the patient having a raised EBV IgA VCA titer of 1:640. Overall, the EBV serologic status of 36 patients (69%) reverted to normal within the studied period (median interval of 54.5 [range, 12-64] months). Conclusions: In the median follow-up period of 54.5 months, only 1 patient (2%) developed NPC. A significant proportion of the patients seroconverted back to normal, none of whom developed NPC.
Persistent Identifierhttp://hdl.handle.net/10722/83578
ISSN
2014 Impact Factor: 2.327
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLo, Sen_HK
dc.contributor.authorHo, WKen_HK
dc.contributor.authorWei, WIen_HK
dc.date.accessioned2010-09-06T08:42:42Z-
dc.date.available2010-09-06T08:42:42Z-
dc.date.issued2004en_HK
dc.identifier.citationArchives Of Otolaryngology - Head And Neck Surgery, 2004, v. 130 n. 6, p. 770-772en_HK
dc.identifier.issn0886-4470en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83578-
dc.description.abstractObjective: To evaluate the current clinical practice of follow-up and the outcomes of patients with raised Epstein-Barr virus (EBV) antibody levels but without pathological evidence of nasopharyngeal carcinoma (NPC) for a possible risk of developing NPC in the future. Design: Retrospective review of prospectively collected database. Setting: Tertiary referral otorhinolaryngology center. Patients: The study population comprised 66 patients (27 male and 39 female; median age, 43.5 [range, 9-78] years) who presented in 1997 with a positive EBV IgA viral capsid antigen titer but a negative nasopharyngeal biopsy result. Main Outcome Measures: The detection of NPC and EBV seroconversion rate. Results: Of the 66 patients studied, 14 had a positive family history of NPC. Fourteen patients (27%) were excluded because of loss of contact or refusal of follow-up. The median follow-up period of the remaining 52 patients was 54.5 months (range, 12-64 months). Of these 52 patients, 39 (75%) had initial nasendoscopic finding described as completely normal. During the follow-up period, NPC was diagnosed in 1 patient (2%) 18 months after first biopsy. The initial nasendoscopy and histological findings in this patient were normal despite the patient having a raised EBV IgA VCA titer of 1:640. Overall, the EBV serologic status of 36 patients (69%) reverted to normal within the studied period (median interval of 54.5 [range, 12-64] months). Conclusions: In the median follow-up period of 54.5 months, only 1 patient (2%) developed NPC. A significant proportion of the patients seroconverted back to normal, none of whom developed NPC.en_HK
dc.languageengen_HK
dc.publisherAmerican Medical Association. The Journal's web site is located at http://www.archoto.comen_HK
dc.relation.ispartofArchives of Otolaryngology - Head and Neck Surgeryen_HK
dc.titleOutcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kongen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0886-4470&volume=130&issue=6&spage=770&epage=772&date=2004&atitle=Outcome+of+patients+with+positive+Epstein-Barr+virus+serologic+status+in+the+absence+of+nasopharyngeal+carcinoma+in+Hong+Kongen_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1001/archotol.130.6.770en_HK
dc.identifier.pmid15210561-
dc.identifier.scopuseid_2-s2.0-2642581806en_HK
dc.identifier.hkuros89249en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-2642581806&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume130en_HK
dc.identifier.issue6en_HK
dc.identifier.spage770en_HK
dc.identifier.epage772en_HK
dc.identifier.isiWOS:000222012900013-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLo, S=9242666000en_HK
dc.identifier.scopusauthoridHo, WK=7402968844en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats